Advertisement

Search Results

Advertisement



Your search for them matches 6128 pages

Showing 3951 - 4000


issues in oncology

Gold Nanoparticle Radiopharmaceuticals for the Selective Treatment of Telomerase-Positive Tumors

Tagging gold nanoparticles with a small dose of radiation has helped researchers trace the precious metal as it delivers a drug right into the heart of cancer cells, according to new laboratory research presented by Bavelaar et al at the 2016 National Cancer Research Institute (NCRI) Cancer...

pancreatic cancer

Vaccines May Boost Immune Responsiveness of Pancreatic Tumors

Pancreatic cancer has been notably unresponsive to immunotherapeutic approaches, but a Stand Up 2 Cancer Dream Team believes their research can change that. Team co-leader Elizabeth Jaffee, MD, Deputy Director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, ...

skin cancer

Combination Strategies Harness the Power of the Oncolytic Virus Talimogene Laherparepvec

The injectable oncolytic immunotherapy talimogene laherparepvec (also known as T-VEC, Imlygic) may become a valuable component of combination immunotherapy approaches in melanoma, a strategy believed to help overcome resistance of tumors to single-agent immunotherapies. “[Talimogene laherparepvec] ...

cns cancers

Preliminary Data Indicate Potential Role for Dabrafenib as Part of Therapy for Pediatric Low-Grade Gliomas With BRAF V600 Mutation

About 10% of children with low-grade gliomas have the BRAF V600E mutation, and preliminary studies suggest that the BRAF inhibitor dabrafenib (Tafinlar) may play an important role in treating this group of patients. A phase I/II trial presented at the 2016 European Society for Medical Oncology...

prostate cancer

Second Opinions From Urologists for Prostate Cancer: Do They Make a Difference?

A new analysis indicates that many men with prostate cancer obtain second opinions from urologists before starting treatment, but surprisingly, second opinions are not associated with changes in treatment choice or improvements in perceived quality of prostate cancer care. Published by...

lung cancer

Pembrolizumab, but Not Nivolumab, Improves Outcomes in Front-Line Setting for PD-L1–Positive Advanced NSCLC

Checkpoint inhibitors have revolutionized the treatment of advanced non–small cell lung cancer (NSCLC), but evidence of their benefit was restricted to the second-line setting. However, early-phase trials with both pembrolizumab (Keytruda) and nivolumab (Opdivo) demonstrated favorable results in...

Introduction

As expensive cancer biologics move off patent, biosimilar products are coming on board. These are highly similar versions of licensed biologics that demonstrate near-fingerprint identity to their reference products in terms of structure and potency. Biosimilars represent a major opportunity for...

kidney cancer

Phase III Study of Sunitinib Is First to Show Benefit in Adjuvant Setting for Treatment of Renal Cell Carcinoma

Sunitinib (Sutent) improved disease-free survival by more than 1 year when used as adjuvant treatment for high-risk locoregional renal cell carcinoma following nephrectomy, but with the cost of toxicity. S-TRAC is the first phase III trial showing a benefit for adjuvant therapy in renal cell...

issues in oncology

Putting Patients First: My Journey in Advocacy

When I lost my only sister to breast cancer in 1986, patients like her had devastatingly few choices. Over the intervening decades, sustained commitment to biomedical research at the National Institutes of Health (NIH) and major technologic advances have led to transformative changes in cancer...

head and neck cancer

New Data Suggest Changes Needed to Guidelines for Determining Prognosis in Patients With Thyroid Cancer

A study from the Duke Cancer Institute (DCI) has found a lack of statistical evidence to support the current practice of treating thyroid cancer patients under age 45 differently from those 45 and older. The study, published recently by Adam et al in the Journal of Clinical Oncology,...

health-care policy

How ASCO Is Preparing Members for MACRA

On October 14, 2016, the Centers for Medicare & Medicaid Services (CMS) announced its final policy on what physicians need to do to begin implementing the Quality Payment Program outlined in the Medicare Access and CHIP Reauthorization Act of 2015 ­(MACRA). The Quality Payment Program is a...

Expert Point of View: Corey J. Langer, MD

Corey J. Langer, MD, Director of Thoracic Oncology and Professor of Medicine at the Hospital of the University of Pennsylvania, Philadelphia, discussed the OAK study with The ASCO Post. Robust Data “In some ways, the OAK data are some of the most robust we have seen in the second-line setting. For ...

breast cancer

Effect of Patient Age on Outcomes in Breast Reconstruction

The most comprehensive study of its kind to date found that older women enjoy the same benefits from breast reconstruction following mastectomy for breast cancer as younger women, without a significant increase in the risk for complications. As with patients across all age groups, the benefits of...

prostate cancer

Potential Link Between Androgen-Deprivation Therapy for Prostate Cancer and Risk for Dementia

In a single-center analysis reported in JAMA Oncology, Nead et al found that the use of androgen-deprivation therapy for prostate cancer was associated with an increased risk for dementia. The study involved electronic medical record data from the Stanford University Health System from 1994 to...

supportive care
survivorship

Sexual Pain Experienced by Women After Cancer Is Common and May Be Ignored

Painful sex in women after cancer treatment is relatively common, often treatable, and needs to be addressed by medical providers, a University of California (UC), Davis, oncologist and researcher suggests. Vanessa Kennedy, MD, a gynecologic oncologist at UC Davis Health System, said that with...

gastroesophageal cancer

Presence of Oral Bacterium in Esophageal Cancer Samples Associated With Shorter Patient Survival

Among Japanese patients with esophageal cancer, those whose cancer tested positive for DNA from the bacterium Fusobacterium nucleatum had shorter cancer-specific survival compared with those whose cancer had no DNA from the bacterium, according to study results published by Yamamura et al in...

cost of care
issues in oncology
health-care policy

Affordable Care Act Increased Access to Cancer Care and Clinical Trial Participation Among Hispanics in California

Implementation of the Affordable Care Act may have led to a significant increase in the number of Hispanic breast cancer patients treated in California at a National Cancer Institute (NCI)-designated cancer center. Further, there was also an increase reported in the number of Hispanic women who...

Lombardi’s Ruesch Center Policy Briefing Features Strategies to Reduce Costs

Two major developments in oncology—the dramatic success of some immunotherapies and targeted drugs and an equally dramatic rise in the cost of care—have created policy issues, more serious than ever, regarding access to care. It is a time “of extraordinary opportunities combined with inequities in ...

A Cancer Diagnosis Brings Two Sisters Back Together

Elizabeth Lesser is an award-winning writer and co-founder of the Omega Institute, the largest adult education center in the United States focusing on health, wellness, spirituality, and creativity. She is the author of several acclaimed books including Broken Open: How Difficult Times Can Help...

palliative care

Quality Improvement Project Results in Timelier Hospice Referrals

A quality improvement project conducted within the OhioHealth system showed that oncologists can change their behavior and refer patients earlier to hospice care. After a relatively minor intervention, 18 medical oncologists in private practice doubled the mean length of stay in hospice care for...

palliative care

Food as Medicine: Study Sets Out to Prove Its Effectiveness

Could the quality of life of patients with advanced-stage cancer be improved by personal delivery of nutritious, medically tailored meals? Researchers at the New York University School of Medicine Perlmutter Cancer Center think so, and they have set out to prove it in a randomized clinical trial....

gastrointestinal cancer

New NCCN Patient Resources Assist Decision-Making for Patients With Stomach Cancer

According to the American Cancer Society, it is estimated that more than 26,000 people will be diagnosed with stomach cancer in the United States this year, with nearly 1 million new cases diagnosed worldwide each year, according to the World Health Organization. Because there are no early symptoms ...

When Breath Becomes Air: Dr. Lucy Kalanithi Reflects on Dr. Paul Kalanithi’s Life and Writing

Perhaps more than any other book in recent memory, When Breath Becomes Air has struck a chord among readers, both inside the medical community and among the public, desiring an honest and philosophical consideration of death. The autobiographical account of Paul Kalanithi, MD, a physician diagnosed ...

Arti Hurria, MD: From Leadership Development Program to Board of Directors

Arti Hurria, MD, a geriatric oncologist at City of Hope in Duarte, California, is the first graduate of ASCO’s Leadership Development Program to be elected to ASCO’s Board of Directors. Within 5 years of completing the program, Dr. Hurria went from learning leadership skills to applying them to...

New Member Categories Provide Specialized Support to Cancer Care Team Members

As part of ASCO’s ongoing effort to fully support all members of the cancer care team, it recently created three new member categories: Advanced Practice Providers, Practice Administrators, and Patient Advocates (see sidebar). Originally part of the Affiliated Health Professionals member category, ...

pancreatic cancer

Precision Promise Clinical Trial Focuses on Precision Medicine, Collaboration, and Data-Sharing in Pancreatic Cancer

The Pancreatic Cancer Action Network recently announced Precision Promise, the first large-scale precision medicine trial designed to transform outcomes for patients with pancreatic cancer. The organization also announced the 12 initial Precision Promise Clinical Trial Consortium sites selected to...

gynecologic cancers

What We Know and What We Need to Know About Neoadjuvant Chemotherapy in Advanced Ovarian Cancer

Ever since the landmark studies of Griffiths and colleagues in the 1970s,1 primary cytoreductive surgery followed by chemotherapy with the objective of achieving minimal residual disease has been the standard approach for women with advanced-stage epithelial ovarian cancer. However, what is...

head and neck cancer

With Changing Strategies for Laryngeal Cancer, Multidisciplinary Team Approach Is Key

The treatment of cancer of the larynx has changed dramatically in recent years. With organ preservation now possible in many cases, it is more important than ever for patients to receive guidance from every corner of the field. In a recent article in the Journal of Oncology Practice (JOP),1 a...

Expert Point of View: Vinai Gondi, MD

Formal discussant of both trials, Vinai Gondi, MD, Director of CNS Radiation Oncology at Northwestern Medicine Cancer Center in Warrenville, Illinois, offered a somewhat more nuanced take on the data from these studies. To begin, he commended the authors of both studies. “These were both...

lung cancer

Retrospective Studies Confirm Survival Benefit of Stereotactic Body Radiotherapy in Early-Stage NSCLC

Stereotactic body radiation therapy is becoming more widely adopted for the treatment of early-stage non–small cell lung cancer (NSCLC). Along with its increasing uptake, survival has significantly increased over the past decade, according to two large retrospective studies presented at the 58th...

breast cancer

Genetic Markers Associated With Pathologic Complete Response to Neoadjuvant Therapy Identified in HER2-Positive Breast Cancer

In an analysis reported in JAMA Oncology, Fumagalli et al identified genetic markers associated with pathologic complete response among women with early-stage HER2-positive breast cancer receiving neoadjuvant therapy in the phase III NeoALTTO trial. Study Details In the NeoALTTO trial, 455...

health-care policy

HHS Finalizes MACRA Rule, ASCO Applauds Focus on High-Quality Patient-Centered Care

Today, the Department of Health & Human Services (HHS) finalized a landmark new payment system for Medicare clinicians that will continue the Administration’s progress in reforming how the health-care system pays for care. The Medicare Access and CHIP Reauthorization Act of ...

leukemia

Delayed Initiation of Tyrosine Kinase Inhibitors Reported in Medicare Patients With Chronic Myeloid Leukemia

In a study using Surveillance, Epidemiology, and End Results (SEER)-Medicaid data reported in the Journal of Clinical Oncology, Winn et al found that 68% of Medicare patients with chronic myeloid leukemia (CML) initiated tyrosine kinase inhibitor treatment within 180 days after diagnosis. Factors...

lung cancer

ESMO 2016: Significant Survival Gains With Atezolizumab vs Docetaxel for Non–Small Cell Lung Cancer

The first phase III study of programmed cell death ligand 1 (PD-L1) inhibitor atezolizumab (Tecentriq) in previously treated non–small cell lung cancer has seen significant improvements in survival compared to standard chemotherapy, reported Barlesi et al at the European Society for Medical...

issues in oncology

Adding Health Navigation Assistance to Community Helpline Connected More People to Cancer Control Measures

A partnership that added health navigation services to 2-1-1 call centers helped a significant number of underserved Texans receive cancer control measures such as Papanicolaou (Pap) tests and smoking cessation help, according to a study (PR12, C49) presented at the 9th Association for Cancer...

lung cancer

Good CNS Response to Alectinib Reported in Previously Treated ALK-Positive Non–Small Cell Lung Cancer

In a pooled analysis reported in the Journal of Clinical Oncology, Gadgeel et al found that alectinib (Alecensa) was associated with good central nervous system (CNS) response in patients with ALK-positive non–small cell lung cancer (NSCLC) previously treated with crizotinib (Xalkori). Study ...

breast cancer
issues in oncology

Affordable Care Act Increased Access to Cancer Care and Clinical Trial Participation Among Hispanics

Implementation of the Affordable Care Act (ACA) in California may have led to a significant increase in the number of Hispanic breast cancer patients at a National Cancer Institute (NCI)-designated cancer center and an increase in the number of Hispanic women who consented to participate in a...

gynecologic cancers

Expect Questions About the FDA Discouraging Use of Ovarian Cancer Screening Tests

The release of a U.S. Food and Drug Administration (FDA) Safety Communication “alerting women about the risks associated with the use of tests being marketed as ovarian cancer screening tests”1 and recommending against using these tests comes not as a result of startling new studies, but from an...

gynecologic cancers
issues in oncology

The FDA Urges Physicians and Patients to Forgo Ovarian Cancer Screening Tests

In a Safety Communication directed at women and physicians, the U.S. Food and Drug Administration (FDA) alerted women “about the risks associated with the use of tests being marketed as ovarian cancer screening tests” and recommended “against using currently offered tests to screen for ovarian...

A Space to Heal

We pass them every day on our way to the hospital, the street dwellers of our town in India. Their home consists of a plastic sheet suspended between four poles on the pavement. One day, two women sat under the plastic sheet in happy conversation. It had rained heavily the previous night, and I...

ASCO President-Elect Bruce E. Johnson, MD, FASCO, Reflects on Volunteer Service, Plans for Presidential Term

Bruce E. Johnson, MD, FASCO, began his term as ASCO President-Elect in June 2016 and will serve as 2017–2018 President. A thoracic cancer specialist, Dr. Johnson is Chief Clinical Research Officer and institute physician at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical...

head and neck cancer

Particular HPV Strain Linked to Improved Prognosis for Oropharyngeal Cancer

When it comes to cancer-causing viruses like human papillomavirus (HPV), researchers are continuing to find that infection with one strain may be better than another. In an analysis of survival data for patients with oropharyngeal cancer, researchers from the University of North Carolina (UNC)...

pain management
survivorship

ASCO Clinical Practice Guideline on Management of Chronic Pain in Survivors of Adult Cancers

As reported in the Journal of Clinical Oncology by Judith A. Paice, PhD, RN, of Northwestern University, and colleagues, ASCO has released a clinical practice guideline on management of chronic pain in survivors of adult cancers.1 The guideline was based on literature review by an expert panel,...

cns cancers

Which Factors Influence Radiotherapy for Brain Metastases?

The advent of more effective systemic therapies, which extend patients’ lives, has also resulted in an increasing incidence of brain metastases, for which clinicians must determine appropriate treatment. Whole-brain radiotherapy has been the traditional treatment modality, but stereotactic...

genomics/genetics

Using Watson to Analyze Genomic Data to Personalize Treatment for Patients With Cancer

Three years ago, IBM’s Watson supercomputer was best known for defeating two former champions on the TV game show Jeopardy! Today, it is grabbing headlines for becoming an important assistant in cancer care. Able to read and understand millions of pages of text within seconds, Watson caught the...

Jacques Galipeau, MD, FRCP(C), Brings Personalized Stem Cell Treatment to UW Carbone

An international leader in harnessing a patient’s own stem cells to fight cancer and autoimmune diseases joined the faculty of the University of Wisconsin (UW) Carbone Cancer Center on September 1. Jacques Galipeau, MD, FRCP(C), came from the Winship Cancer Center at Emory University, where he...

multiple myeloma

Study Finds Adding Daratumumab to Bortezomib/Dexamethasone Improves Progression-Free Survival in Relapsed/Refractory Multiple Myeloma

In the phase III CASTOR trial reported in The New England Journal of Medicine, Antonio Palumbo, MD, of the University of Turin, and colleagues found that adding the anti-CD38 antibody daratumumab (Darzalex) to bortezomib (Velcade) and dexamethasone markedly improved progression-free survival among ...

issues in oncology
supportive care
palliative care

Why Care About the Caregivers?

Caregivers of patients with cancer provide invaluable health-care services, but they are an underserved and undervalued group, with many unmet needs. Early palliative care may provide important benefits to these often tireless individuals, according to J. Nicholas Dionne-Odom, PhD, RN, ACHPN, of...

palliative care

Benefits of Early Palliative Care Interventions Extend Beyond the Patient

A session at the 2016 Palliative Care in Oncology Symposium focused on the special needs of cancer caregivers. In a large survey, caregivers of persons with cancer reported higher levels of stress and significantly more duties than caregivers of other patients. But, according to research from...

palliative care

Palliative Care: Let’s Use the Tools We Already Have

Clinicians and researchers in the field of palliative and supportive care are enjoying the recognition the field is now receiving and expecting the future to be ripe with opportunity. But one thought leader in this specialty had a suggestion for attendees at the 2016 Palliative Care in Oncology...

Advertisement

Advertisement




Advertisement